2.13
Jaguar Health Inc stock is traded at $2.13, with a volume of 38,363.
It is up +2.90% in the last 24 hours and up +8.67% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
38,363
Relative Volume:
0.26
Market Cap:
$4.63M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.1316
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
-2.74%
1M Performance:
+8.67%
6M Performance:
-61.76%
1Y Performance:
-93.18%
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
JAGX
Jaguar Health Inc
|
2.13 | 7.67M | 10.48M | -37.74M | -29.03M | -16.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Why Jaguar Health Inc. stock remains a top recommendationEarnings Beat & AI Optimized Trade Strategies - newser.com
Will Jaguar Health Inc. stock pay special dividends2025 Key Highlights & Safe Entry Zone Tips - newser.com
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease - Worcester Telegram
Evaluating Jaguar Health Inc. with trendline analysis2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Analyzing Jaguar Health Inc. with risk reward ratio chartsJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Price action breakdown for Jaguar Health Inc.Quarterly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Lansing State Journal
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts - Peoria Journal Star
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition - Shreveport Times
Using fundamentals and technicals on Jaguar Health Inc.Exit Point & High Win Rate Trade Alerts - newser.com
Chart based analysis of Jaguar Health Inc. trendsQuarterly Trade Review & Stock Market Timing Techniques - newser.com
Published on: 2025-10-10 04:56:36 - newser.com
Real time social sentiment graph for Jaguar Health Inc.New Guidance & AI Driven Stock Movement Reports - newser.com
What machine learning models say about Jaguar Health Inc.July 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Momentum divergence signals in Jaguar Health Inc. chartWatch List & Free Verified High Yield Trade Plans - newser.com
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs - ACCESS Newswire
How to build a custom watchlist for Jaguar Health Inc.New Guidance & Long-Term Safe Investment Plans - newser.com
Tools to assess Jaguar Health Inc.’s risk profile2025 Bull vs Bear & Growth Focused Entry Point Reports - newser.com
Jaguar Health registers 2.62M shares for resale following private placements - MSN
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID) - The Florida Times-Union
Jaguar Health reports positive results in MVID treatment trial By Investing.com - Investing.com Nigeria
Jaguar Health reports positive results in MVID treatment trial - Investing.com
Jaguar Health (JAGX) Advances Crofelemer Trial Following FDA Mee - GuruFocus
37% PS reduction; Jaguar Health's crofelemer powder reduced TPN 30% in pediatric MVID trial - Stock Titan
Is Jaguar Health Inc. stock a buy before product launchesWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Can technical indicators confirm Jaguar Health Inc.’s reversalJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):